These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24912050)

  • 1. Recent advances in head and neck squamous cell carcinoma--a review.
    Safdari Y; Khalili M; Farajnia S; Asgharzadeh M; Yazdani Y; Sadeghi M
    Clin Biochem; 2014 Sep; 47(13-14):1195-202. PubMed ID: 24912050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
    Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma.
    Bonner JA; Yang ES; Trummell HQ; Nowsheen S; Willey CD; Raisch KP
    Radiother Oncol; 2011 Jun; 99(3):339-43. PubMed ID: 21704410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durable complete remission induced by cetuximab monotherapy in a patient infected with HIV and diagnosed with recurrent squamous cell carcinoma of the head and neck.
    Rubinstein PG; Lindgren V; Setty S; Yao M; Pytynia KB; Radosevich JA; Kadkol SS; Feldman LE
    J Clin Oncol; 2011 Mar; 29(9):e222-5. PubMed ID: 21189379
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents.
    Harrington KJ; Kazi R; Bhide SA; Newbold K; Nutting CM
    Indian J Cancer; 2010; 47(3):248-59. PubMed ID: 20587899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of cetuximab in head and neck cancer: a 2007 perspective.
    Panikkar RP; Astsaturov I; Langer CJ
    Cancer Invest; 2008 Feb; 26(1):96-103. PubMed ID: 18181051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab in squamous cell carcinoma of the head and neck.
    Hitt R; Martín P; Hidalgo M
    Future Oncol; 2006 Aug; 2(4):449-57. PubMed ID: 16922611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab plus radiotherapy for head and neck cancer.
    Hartig F; Pechlaner C
    N Engl J Med; 2006 May; 354(20):2187; author reply 2187. PubMed ID: 16710909
    [No Abstract]   [Full Text] [Related]  

  • 11. The efficacy of combined treatment with cetuximab (erbitux) and radiation therapy in patients with head and neck cancer.
    Koukourakis G; Kouloulias V; Koukourakis M; Kouvaris J; Zacharias G; Gouliamos A
    J BUON; 2009; 14(1):19-25. PubMed ID: 19373942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transforming growth factor alpha stimulation of mucosal tissue cultures from head and neck squamous cell carcinoma patients increases chemoresistance to cisplatin.
    Baumeister P; Reiter M; Schwenk-Zieger S; Harréus U
    Chemotherapy; 2010; 56(4):268-74. PubMed ID: 20693797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
    Huang SM; Harari PM
    Clin Cancer Res; 2000 Jun; 6(6):2166-74. PubMed ID: 10873065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
    Bernier J
    Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting EGFR-positive cancer cells with cetuximab-ZZ-PE38: Results of in vitro and in vivo studies.
    Barnea I; Ben-Yosef R; Karaush V; Benhar I; Vexler A
    Head Neck; 2013 Aug; 35(8):1171-7. PubMed ID: 22965815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controversies and role of HPV16 in recurrent/metastatic squamous cell cancers of the head and neck.
    Misiukiewicz K; Bonomi M; Demicco E; Posner M
    Ann Oncol; 2014 Aug; 25(8):1667-8. PubMed ID: 24875798
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment for head and neck cancer.
    FDA Consum; 2006; 40(3):7. PubMed ID: 16909488
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Cohen EE
    J Clin Oncol; 2006 Jun; 24(17):2659-65. PubMed ID: 16763280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in chemotherapy for head and neck cancer.
    Bhide SA; Nutting CM
    Oral Oncol; 2010 Jun; 46(6):436-8. PubMed ID: 20400360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging molecular targeted therapies in the treatment of head and neck cancer.
    Bozec A; Peyrade F; Fischel JL; Milano G
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):299-310. PubMed ID: 19519286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.